GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
73.27
-0.90 (-1.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close74.17
Open74.15
Bid73.10 x 1800
Ask73.74 x 800
Day's range73.15 - 74.80
52-week range64.27 - 89.54
Volume4,869,978
Avg. volume6,394,059
Market cap94.983B
Beta (3Y Monthly)1.40
PE ratio (TTM)43.77
EPS (TTM)1.67
Earnings date25 Oct 2018
Forward dividend & yield2.28 (3.13%)
Ex-dividend date2018-09-13
1y target est87.91
Trade prices are not sourced from all markets
  • Business Wire7 hours ago

    Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting

    Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis.

  • Motley Foolyesterday

    Could a Diagnostic Be Key to Winning This Big Healthcare Market?

    A small company is working on new ways to tackle a life-threatening liver disease.

  • How Gilead Sciences Is Leveraging the NASH Opportunity in 2018
    Market Realistyesterday

    How Gilead Sciences Is Leveraging the NASH Opportunity in 2018

    Gilead Sciences (GILD) is currently trading at PE (price-to-earnings), forward PE, and price-to-sales ratios of 12.44x, 10.95x, and 4.07x, respectively. GILD’s price-to-book, price-to-cash flow, and price-to-free-cash-flow ratios were 4.36x, 3.65x, and 16.95x, respectively.

  • Biogen: Analysts’ Recommendations on October 19
    Market Realistyesterday

    Biogen: Analysts’ Recommendations on October 19

    Wall Street analysts expect Biogen’s (BIIB) third-quarter revenues to increase ~8.2% to $3.33 billion—compared to its revenues of $3.07 million during the third quarter of 2017. Biogen’s stock price has decreased nearly 4.1% in the last 12 months. Analysts’ recommendations show a 12-month target price of $390.88 per share—compared to the last price of $330.15 per share as of October 18.

  • How Gilead Sciences Stock Performed in the First Half of October
    Market Realistyesterday

    How Gilead Sciences Stock Performed in the First Half of October

    On October 12, Gilead Sciences (GILD) closed at $73.59, which was 1.5% higher than its closing price on October 11. This increase in its stock price followed the company’s announcement that it planned to release data from its R&D programs targeting various liver conditions at The Liver Meeting 2018 in San Francisco. Its stock price dropped 1.1% and closed at $72.78 on October 15.

  • Analyzing Biogen before Its Third-Quarter Earnings
    Market Realist2 days ago

    Analyzing Biogen before Its Third-Quarter Earnings

    Biogen (BIIB), a leading biotechnology company, is scheduled to release its third-quarter earnings on October 23. Analysts expect the adjusted EPS to be $6.78 on revenues of $3.33 billion during the third quarter.

  • Pfizer Reported Revenue Growth in Global Markets
    Market Realist2 days ago

    Pfizer Reported Revenue Growth in Global Markets

    Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.

  • Motley Fool2 days ago

    Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways?

    How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.

  • Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
    Zacks2 days ago

    Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, Gilead Sciences (GILD) closed at $74.17, marking a -1.92% move from the previous day.

  • Is Sangamo Therapeutics Inc. a Buy?
    Motley Fool3 days ago

    Is Sangamo Therapeutics Inc. a Buy?

    Can this beaten-down gene-editing and gene therapy biotech bounce back?

  • CNBC3 days ago

    Cramer's lightning round: For growth and yield, go with Verizon over Kraft Heinz

    Jim Cramer speeds through his take on callers' favorite stocks, including his favorite pick for "decent growth with good yield."

  • Can This Tiny Biotech Revolutionize a $35 Billion Market?
    Motley Fool4 days ago

    Can This Tiny Biotech Revolutionize a $35 Billion Market?

    This upstart is developing a diagnostic test and treatment for nonalcoholic steatohepatitis, or NASH, an increasingly common liver disease.

  • Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock
    Motley Fool5 days ago

    Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock

    Gilead's high-flying days are seemingly over. Intercept Pharmaceuticals, on the other hand, is only getting started.

  • Gauging Analysts’ Views of Sarepta Stock in October
    Market Realist5 days ago

    Gauging Analysts’ Views of Sarepta Stock in October

    Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.

  • Trump administration: Drug makers should disclose prices in TV ads
    Yahoo Finance5 days ago

    Trump administration: Drug makers should disclose prices in TV ads

    just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.

  • A Look at Sarepta Therapeutics’ Stock Performance
    Market Realist6 days ago

    A Look at Sarepta Therapeutics’ Stock Performance

    Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.

  • Key Collaborations Bode Well for Sarepta Therapeutics
    Market Realist6 days ago

    Key Collaborations Bode Well for Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.

  • 2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better
    Motley Fool6 days ago

    2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better

    A bad week for the broad market made some generous payouts even more attractive.

  • Analyzing Sarepta’s Product Pipeline
    Market Realist6 days ago

    Analyzing Sarepta’s Product Pipeline

    Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene. 

  • Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
    Zacks8 days ago

    Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Gilead Sciences (GILD) closed at $73.59, marking a +1.5% move from the previous day.

  • Understanding Sarepta Therapeutics’ Operational Performance
    Market Realist8 days ago

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.

  • Business Wire9 days ago

    Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018

    Gilead Sciences, Inc. (GILD) announced today that its third quarter 2018 financial results will be released on Thursday, October 25, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2018 and provide a general business update. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 1789278 to access the call.

  • Business Wire9 days ago

    Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018

    -- More Than 50 Abstracts Across NASH, PSC, HBV and HCV Reflect Ongoing Commitment to Advancing the Care of People with Liver Disease--

  • Healthcare Stocks in the Red amid Broader Market Sell-Off
    Market Realist10 days ago

    Healthcare Stocks in the Red amid Broader Market Sell-Off

    Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.

  • Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
    Zacks11 days ago

    Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates

    Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.